Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple MyelomaJesús F. San Miguel, Hermann Einsele, Carlos Fernández de Larrea et al.|New England Journal of Medicine|2023Cited by 719
Minimal residual disease in multiple myeloma: bringing the bench to the bedsideSham Mailankody, Ola Landgren, Neha Korde et al.|Nature Reviews Clinical Oncology|2015Cited by 114
Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical TrialSham Mailankody, Eric L. Smith, Arnab Ghosh et al.|Blood|2018Cited by 100